

1 **Strength and durability of antibody responses to BNT162b2 and CoronaVac**

2

3 Benjamin J. Cowling*^{1,2}, Irene O. L. Wong*¹, Eunice Y. C. Shiu¹, Amber Y. T. Lai¹, Samuel

4 M. S. Cheng¹, Sara Chaothai¹, Kelvin K. H. Kwan¹, Mario Martín-Sánchez¹, Leo L. M.

5 Poon^{1,3,4}, Dennis K. M. Ip¹, Gabriel M. Leung^{1,2}, Nancy H. L. Leung^{†1,2}, J. S. Malik

6 Peiris^{†1,3,4}

7

8 *Joint first authors with equal contribution

9 †Joint senior authors with equal contribution

10

11 **Affiliations:**

12 1. WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of
13 Public Health, LKS Faculty of Medicine, The University of Hong Kong; Hong Kong Special
14 Administrative Region, China.

15 2. Laboratory of Data Discovery for Health; Hong Kong Science and Technology Park, Hong
16 Kong Special Administrative Region, China.

17 3. HKU-Pasteur Research Pole, School of Public Health, Li Ka Shing Faculty of Medicine,
18 The University of Hong Kong; Hong Kong Special Administrative Region, China.

19 4. Centre for Immunology and Infection; Hong Kong Science and Technology Park, Hong
20 Kong Special Administrative Region, China.

21

22 Corresponding authors: N. Leung leungnan@hku.hk and B. Cowling, bcowling@hku.hk

23 Word count (abstract): 50

24 Word count (main text): 1819

25 **NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

26 **ABSTRACT**

27 We studied 2780 adults in Hong Kong who received CoronaVac inactivated virus vaccine
28 (Sinovac) and BNT162b2 mRNA vaccine (“Comirnaty”, BioNTech/Fosun Pharma). We
29 found stronger and more durable antibody responses to two doses of the mRNA vaccine, and
30 slightly stronger initial antibody responses to each vaccine in younger adults and women.

31

32 INTRODUCTION

33 Vaccines for coronavirus disease 2019 (COVID-19) provide protection against infection and
34 can also ameliorate disease severity if breakthrough infections occur [1]. Protection against
35 infection is likely mediated through antibodies, and the effectiveness of different vaccine
36 technologies against mild symptomatic infection has been shown to correlate with the
37 strength of neutralizing antibody responses to those vaccines [2-4]. In particular, antibody
38 responses after receipt of inactivated COVID-19 vaccines have been shown to be somewhat
39 weaker than antibody responses to mRNA vaccines [5, 6], although T cell responses are more
40 comparable between the two vaccine technologies [6]. There are relatively fewer studies
41 comparing rates of antibody waning over time, particularly with inactivated vaccines [7, 8].

42
43 In Hong Kong, two vaccines have been made available to the general public through a mass
44 vaccination program since early 2021, the CoronaVac inactivated virus vaccine (Sinovac)
45 and the BNT162b2 mRNA vaccine (“Comirnaty”, BioNTech/Fosun Pharma). As of 11
46 February 2022, 11.7 million vaccine doses have been administered, with 74% of the
47 population of about 7.4 million residents receiving at least one vaccine dose, 67% receiving
48 at least two doses, and 16% receiving three doses. Of the 11.7 million doses administered to
49 date, 4.5 million were CoronaVac and 7.2 million were BNT162b2. Here, we followed up
50 vaccinated individuals in Hong Kong to study the strength and durability of antibody
51 responses to vaccination for up to six months after the second dose.

52 53 METHODS

54 *Recruitment and Follow-up of Participants*

55 We analyzed data from two ongoing community-based cohort studies of infections and
56 immunity. In the “Evaluating Population Immunity in Hong Kong” (EPI-HK) cohort study

57 which was initially designed to study influenza and later also expanded to COVID-19, we
58 enrolled individuals from the community starting in July 2020, and included individuals
59 regardless of COVID-19 vaccination status. For analyses reported here we include the subset
60 of study participants who were aged ≥ 18 y and have received two doses of COVID-19
61 vaccination. Blood samples are collected from each participant at approximately six-month
62 intervals, with additional blood samples collected one month after any dose of COVID-19
63 vaccination.

64

65 In the “CCOVID-19 Vaccine Research” (COVAR) cohort study which aims to study vaccine
66 immunogenicity and long-term antibody responses in COVID-19 vaccine recipients, we
67 enrolled adults ≥ 18 y of age from the general community and from Community Vaccination
68 Centres. In the initial protocol we aimed to enroll individuals shortly before receiving the first
69 dose of any COVID-19 vaccine in Hong Kong, this was later relaxed to allow enrollment of
70 individuals after receiving one or more vaccine doses. Blood samples are collected from each
71 participant at baseline, one month after any dose of COVID-19 vaccination, and at 6, 12, 24
72 and 36 months after the second dose of vaccination.

73

74 Similar data are collected from participants in both studies, including information on
75 demographics and socio-economic status, underlying medical conditions and regular
76 medication use, and the type and dates of any COVID-19 vaccine doses received. Participants
77 receive coupons worth HK\$100 (approximately US\$13) at each blood draw.

78

79 ***Ethics***

80 Written informed consent was obtained from all participants. The study protocols were
81 approved by the Institutional Review Board of the University of Hong Kong.

82

83 ***Laboratory Methods***

84 Sera were extracted from the clotted blood samples within 24 hours after collection, divided
85 into 2-4 aliquots, and stored at -80°C until subsequent serologic testing. Samples were tested
86 with an ELISA for spike receptor binding domain and a surrogate virus neutralization test
87 (sVNT) as previously described [9]. We previously demonstrated that both assays can be
88 used as proxy for neutralizing antibody against SARS-CoV-2 as measured by plaque
89 reduction neutralization test with live virus [10].

90

91 We obtained sVNT kits from GeneScript USA, Inc, New Jersey and the tests carried out
92 according to the manufacturer's instructions. The % inhibition of each serum was calculated
93 as Inhibition (%) = $(1 - \text{Sample OD value} / \text{Negative Control OD value}) \times 100$. Inhibition (%)
94 of $\geq 30\%$ was regarded as a positive result while $< 30\%$ was considered negative [9].

95

96 ELISA was carried out as previously described [9]. 96-well ELISA plates (Nunc MaxiSorp,
97 Thermo Fisher Scientific) were coated overnight with 100 ng per well of the purified
98 recombinant RBD protein in PBS buffer. The plates were then blocked with 100 μl of
99 Chonblock blocking/sample dilution ELISA buffer (Chondrex Inc, Redmon, US) and
100 incubated at room temperature for 2 h. Each serum or plasma sample diluted 1:100 in
101 Chonblock blocking/sample dilution ELISA buffer was added to duplicate wells and
102 incubated for 2 h at 37°C. After washing with PBS containing 0.1% Tween 20, horseradish
103 peroxidase (HRP)-conjugated goat anti-human IgG (1:5,000, GE Healthcare) was added for 1
104 h at 37°C. The ELISA plates were then washed in PBS with 0.1% Tween 20. Subsequently,
105 100 μL of HRP substrate (Ncm TMB One; New Cell and Molecular Biotech Co. Ltd,
106 Suzhou, China) was added into each well. After 15 min incubation, the reaction was stopped

107 by adding 50 μ L of 2 M H₂SO₄ solution and analyzed on a Sunrise (Tecan, Männedorf,
108 Switzerland) absorbance microplate reader at 450 nm wavelength. Optical density above 0.5
109 was considered a positive result.

110

111 *Statistical Analysis*

112 We assessed mean antibody levels measured by ELISA (optical density, OD) and sVNT (%
113 inhibition) after the first and second dose of COVID-19 vaccination. It was recommended
114 that individuals should receive their second dose 21 and 28 days after the first dose for
115 BNT162b2 and CoronaVac, respectively. We did not include any samples collected after
116 receipt of a third dose, or any samples collected after a confirmed SARS-CoV-2 infection.
117 Differences in antibody levels between vaccine type overall or within each category of age or
118 sex were compared using t-tests. To evaluate the duration after which antibody level fall
119 below the manufacturer's defined sVNT threshold of seropositivity at 30% inhibition
120 (Supplementary Information), we fitted a smoothing spline to antibody levels over time
121 starting at 14 days and up to 180 days after receipt of the second dose. Statistical analyses
122 were conducted using R version 4.1.2 (R Foundation for Statistical Computing, Vienna,
123 Austria).

124

125 **RESULTS**

126 We included data from 2780 vaccinated individuals including 2172 from the EPI-HK study
127 and 608 from the COVAR study who had provided at least one post-vaccination blood
128 sample by 23 December 2021, contributing 1528 blood samples collected from 799
129 individuals who received CoronaVac (median age 59.4 years, 46.6% male), and 3939 blood
130 samples collected from 1981 individuals who received BNT162b2 (median age 49.3 years,

131 44.7% male). Additional information on the demographics of study participants is provided
132 in Appendix Table 1.

133

134 Antibody levels increased to moderate levels following two doses of CoronaVac (Figure 1A)
135 compared to very high levels following two doses of BNT162b2 (Figure 1B). The mean
136 sVNT antibody levels measured against ancestral virus at 14-42 days after the second dose
137 for CoronaVac were 53.7% (95% confidence interval, CI: 51.2, 56.3) and for BNT162b2
138 were 94.3% (95% CI: 93.8, 94.7), with significant differences between the two vaccines
139 overall and within each age group (Appendix Table 2). For both vaccines, the observed post-
140 vaccination levels had a slight inverse correlation with age, and average levels were slightly
141 higher in females than in males (p -values <0.01 for these within-group comparisons)
142 (Appendix Table 2). Overall, antibody levels remained below the threshold of 30% after the
143 second dose in 23% and 0.5% of participants who received CoronaVac and BNT162b2,
144 respectively. In particular, the antibody levels did not reach the threshold of 30% in 51% of
145 older adults ≥ 60 years old who received CoronaVac vaccination.

146

147 Antibody levels started to decline gradually over time starting from one month after recipient
148 of the second dose for both vaccines, with faster antibody waning in the recipients of
149 CoronaVac (Figure 1C and 1D). In recipients of CoronaVac, the fitted curve for average
150 antibody level fell below the threshold of 30% by around 4 months after second dose, while
151 remaining elevated for at least six months in recipients of BNT162b2. Consistently, we
152 continued to observe significant differences in antibody levels 4-6 months after vaccination
153 between the two vaccines overall and within each age group (Appendix Table 3). The mean
154 sVNT antibody levels at 120-180 days after the second dose overall were 21.2% (95% CI:
155 16.9, 25.6) and 81.1% (95% CI: 78.0, 84.3) for CoronaVac and BNT162b2 respectively.

156 Specifically, sVNT antibody levels fell to below the threshold of 30% in 84% of participants
157 who received CoronaVac, versus none among those who received BNT162b2. However, with
158 a smaller sample size here we were not able to identify statistically significant differences by
159 age or sex within each vaccine group. We also examined antibody levels by ELISA, finding
160 similar comparative patterns of boosting and waning between the two vaccine types
161 (Appendix Figure 1).

162

163 **DISCUSSION**

164 Evidence on antibody boosting and waning after vaccination is important as it affects the
165 potential timing of subsequent booster vaccine doses. Here, we demonstrate higher levels of
166 antibody to SARS-CoV-2 following two doses of the mRNA vaccine BNT162b2 compared
167 to two doses of the inactivated vaccine CoronaVac [5, 6], and longer durability of responses
168 for BNT162b2 for at least six months following the receipt of a second dose [7, 11]. Our
169 finding of rapid waning of antibody following receipt of CoronaVac echoes previous reports
170 [7, 11] and indicates that a third dose would likely be needed sooner, and indeed in Hong
171 Kong third doses have been recommended at ≥ 3 months after the second dose of CoronaVac.
172 It is important to recognize, however, that protection against severe COVID could be retained
173 even in spite of waning of protection from infection [12].

174

175 We found stronger responses to two doses of both vaccines in females and in younger adults,
176 consistent with other studies. For example Uwamino et al reported similar observations in a
177 cohort of 673 recipients of BNT162b2 [13], while Xu et al. reported stronger and more
178 durable antibody responses in females and younger recipients of an inactivated vaccine [14].
179 There are a number of potential underlying biological mechanisms that could lead to a sex

180 difference, and stronger antibody responses in women have been reported for other vaccines
181 [15].

182

183 There are a number of limitations of our study. First, we did not measure neutralizing
184 antibody against live SARS-CoV-2 but used a surrogate neutralization assay which has a high
185 correlation with live virus neutralization titers [16]. We did not assess antibodies against
186 variants such as Delta or Omicron, but expect antibody levels to be reduced against variants
187 as reported in other studies [16, 17]. We did not assess T cell responses which could
188 contribute to protection against severe disease and could be less affected by variants [18].

189

190 In conclusion, we identified weaker boosting and faster waning of antibodies against SARS-
191 CoV-2 in recipients of CoronaVac compared to BNT162b2, and would expect this to
192 correlate with lower levels of protection against symptomatic infection for CoronaVac. In
193 individuals of any age or sex, BNT162b2 responses were stronger and more durable than
194 responses to CoronaVac. The weaker and less durable responses following CoronaVac
195 support earlier provision of third doses to persons who previously received two doses of this
196 vaccine.

197

198

199 **ACKNOWLEDGMENTS**

200 We acknowledge colleagues including Jemmi Ho, Joyce Lau, Shadow Lau, Leslie Leung
201 (EPI-HK study), Alex Chan, Vincent Fung, Raina Kwan, Lilly Wang, Benny Wong (COVAR
202 study) and other part-time colleagues for technical support in preparing and conducting this
203 study and enrolling participants; Anson Ho for setting up the database; Leo Luk, Karl Chan,
204 John Li, Yonna Leung, Leo Tsang and Zacary Chai for laboratory support; Hetti Cheung,
205 Victoria Wong, Bobo Yeung at HKU Health System; and King-man Ho, Cindy Man and
206 other colleagues at the Community Vaccination Centres at Ap Lei Chau Sports Centre,
207 Gleneagles Hospital and Hong Kong Central Library for facilitating the two cohort studies.

208

209 **FINANCIAL SUPPORT**

210 This project was financially supported by the Health and Medical Research Fund of the Food
211 and Health Bureau of the Hong Kong SAR Government (project nos. COVID1903001 and
212 COVID190126), the Theme-based Research Scheme (project no. T11-712/19-N) from the
213 Research Grants Council from the University Grants Committee of Hong Kong, and the
214 Wellcome Trust (grant number: 221013/Z/20/Z). BJC is supported by an RGC Senior
215 Research Fellowship (grant number: HKU SRFS2021-7S03).

216

217 **POTENTIAL CONFLICTS OF INTEREST**

218 BJC consults for AstraZeneca, Fosun Pharma, GSK, Moderna, Pfizer, Roche and Sanofi
219 Pasteur. The authors report no other potential conflicts of interest.


220

221 **REFERENCES**

- 222 1. Wouters OJ, Shadlen KC, Salcher-Konrad M, et al. Challenges in ensuring global access to
223 COVID-19 vaccines: production, affordability, allocation, and deployment. *Lancet* **2021**;
224 397:1023-34.
- 225 2. Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly
226 predictive of immune protection from symptomatic SARS-CoV-2 infection. *Nat Med* **2021**;
227 27:1205-11.
- 228 3. Feng S, Phillips DJ, White T, et al. Correlates of protection against symptomatic and
229 asymptomatic SARS-CoV-2 infection. *Nat Med* **2021**; 27:2032-40.
- 230 4. Earle KA, Ambrosino DM, Fiore-Gartland A, et al. Evidence for antibody as a protective
231 correlate for COVID-19 vaccines. *Vaccine* **2021**; 39:4423-8.
- 232 5. Lim WW, Mak L, Leung GM, Cowling BJ, Peiris M. Comparative immunogenicity of
233 mRNA and inactivated vaccines against COVID-19. *Lancet Microbe* **2021**; 2:e423.
- 234 6. Mok CKP, Cohen CA, Cheng SMS, et al. Comparison of the immunogenicity of
235 BNT162b2 and CoronaVac COVID-19 vaccines in Hong Kong. *Respirology* **2021**.
- 236 7. Kwok SL, Cheng SM, Leung JN, et al. Waning antibody levels after COVID-19
237 vaccination with mRNA Comirnaty and inactivated CoronaVac vaccines in blood donors,
238 Hong Kong, April 2020 to October 2021. *Euro Surveill* **2022**; 27.
- 239 8. Zeng G, Wu Q, Pan H, et al. Immunogenicity and safety of a third dose of CoronaVac, and
240 immune persistence of a two-dose schedule, in healthy adults: interim results from two
241 single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials. *Lancet*
242 *Infect Dis* **2021**.
- 243 9. Lau EH, Hui DS, Tsang OT, et al. Long-term persistence of SARS-CoV-2 neutralizing
244 antibody responses after infection and estimates of the duration of protection.
245 *EClinicalMedicine* **2021**; 41:101174.

- 246 10. Perera RAPM, Ko R, Tsang OTY, et al. Evaluation of a SARS-CoV-2 Surrogate Virus
247 Neutralization Test for Detection of Antibody in Human, Canine, Cat, and Hamster Sera. *J*
248 *Clin Microbiol* **2021**; 59.
- 249 11. Mok CKP, Cheng SMS, Chen C, et al. A RCT Using CoronaVac or BNT162b2 Vaccine
250 as a Third Dose in Adults Vaccinated with Two Doses of CoronaVac. *Am J Respir Crit Care*
251 *Med* **2022**.
- 252 12. Tartof SY, Slezak JM, Fischer H, et al. Effectiveness of mRNA BNT162b2 COVID-19
253 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort
254 study. *Lancet* **2021**; 398:1407-16.
- 255 13. Uwamino Y, Kurafuji T, Sato Y, et al. Young age, female sex, and presence of systemic
256 adverse reactions are associated with high post-vaccination antibody titer after two doses of
257 BNT162b2 mRNA SARS-CoV-2 vaccination: An observational study of 646 Japanese
258 healthcare workers and university staff. *Vaccine* **2022**.
- 259 14. Xu QY, Xue JH, Xiao Y, et al. Response and Duration of Serum Anti-SARS-CoV-2
260 Antibodies After Inactivated Vaccination Within 160 Days. *Front Immunol* **2021**; 12:786554.
- 261 15. Hussain M, Fatima M, Muhammad Iqbal S, et al. COVID-19 vaccine trials and sex-
262 disaggregated data. *Expert Rev Vaccines* **2021**:1-4.
- 263 16. Cheng SMS, Mok CKP, Leung YWY, et al. Neutralizing antibodies against the SARS-
264 CoV-2 Omicron variant following homologous and heterologous CoronaVac or BNT162b2
265 vaccination. *Nat Med* **2022**.
- 266 17. Perez-Then E, Lucas C, Monteiro VS, et al. Neutralizing antibodies against the SARS-
267 CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2
268 booster vaccination. *Nat Med* **2022**.
- 269 18. Gao Y, Cai C, Grifoni A, et al. Ancestral SARS-CoV-2-specific T cells cross-recognize
270 the Omicron variant. *Nat Med* **2022**.


271



272

273 **Figure 1: Post-vaccination rises followed by longer-term decay in neutralizing antibody**
274 **levels against the ancestral SARS-CoV-2 virus after receipt of two doses of CoronaVac**
275 **or BNT162b2 vaccination, measured by a surrogate virus neutralization test.** Panels A
276 and B show antibody levels prior to receipt of vaccination (“Pre-vaccination”), 14-35 days
277 after receipt of the first dose but no later than the day of receipt of second dose (“After 1st
278 dose”), and 14-42 days after receipt of the second dose (“After 2nd dose”), for an inactivated
279 (CoronaVac) or mRNA (BNT162b2) vaccine respectively. Green lines represent mean %
280 inhibition in the respective time periods. Panels C and D show antibody levels between 14-
281 180 days after the receipt of a second dose of CoronaVac or BNT162b2, respectively. Solid
282 purple lines represent the spline fit and dotted lines the associated 95% pointwise bootstrap
283 confidence intervals for the estimated changes over time in mean antibody levels. In all four
284 panels, the grey horizontal line indicates the manufacturer’s defined threshold for
285 seropositivity at 30% inhibition.

286



287

288 **Appendix Figure 1: Post-vaccination rises followed by longer-term decay in IgG**
289 **antibody levels against the ancestral SARS-CoV-2 virus after receipt of two doses of**
290 **CoronaVac or BNT162b2 vaccination, measured by an ELISA assay against the**
291 **receptor binding domain of the spike protein.** Panels A and B show antibody levels prior
292 to receipt of vaccination (“Pre-vaccination”), 14-35 days after receipt of the first dose but no
293 later than the day of receipt of second dose (“After 1st dose”), and 14-42 days after receipt of
294 the second dose (“After 2nd dose”), for an inactivated (CoronaVac) or mRNA (BNT162b2)
295 vaccine respectively. Green lines represent mean optical density (OD) in the respective time
296 periods. Panels C and D show antibody levels between 14-180 days after the receipt of a
297 second dose of CoronaVac or BNT162b2, respectively. Solid purple lines represent the spline
298 fit and dotted lines the associated 95% pointwise bootstrap confidence intervals for the
299 estimated changes over time in mean antibody levels. In all four panels, the grey horizontal
300 line indicates the manufacturer’s defined threshold for seropositivity at OD of 0.5.
301

302 **Appendix Table 1. Characteristics of study participants who received two doses of**
 303 **inactivated vaccine (CoronaVac) or mRNA vaccine (BNT162b2) (n=2780).** Participants
 304 from both the EPI-HK and COVAR studies who have antibody levels measured at least once
 305 between 14-180 days after recipient of the second dose are included.

	Inactivated vaccine (CoronaVac) (n=799)		mRNA vaccine (BNT162b2) (n=1981)	
	Number	(%)	Number	(%)
Age group, years				
18-29	29	(3.6%)	279	(14.1%)
30-39	43	(5.4%)	346	(17.5%)
40-49	114	(14.3%)	396	(20.0%)
50-59	231	(28.9%)	437	(22.1%)
60-69	284	(35.5%)	419	(21.2%)
≥70	98	(12.3%)	104	(5.2%)
Male sex	372	(46.6%)	885	(44.7%)
Have a clinically-diagnosed chronic condition	235	(29.4%)	412	(20.8%)
Ever been a regular smoker (of one or more cigarettes a day)	31	(3.9%)	100	(5.0%)
Interval between first and second vaccination, days				
14-21	3	(0.4%)	1164	(58.8%)
22-28	564	(70.6%)	704	(35.5%)
29-35	211	(26.4%)	96	(4.8%)
36-42	21	(2.6%)	17	(0.9%)

306

307 **Appendix Table 2. Mean sVNT levels measured against ancestral SARS-CoV-2 virus at**
 308 **14-42 days after the receipt of the second vaccine dose of an inactivated (CoronaVac) or**
 309 **mRNA (BNT162b2) vaccine, overall and by age and sex (n=1431).** Only participants from
 310 both the EPI-HK and COVAR studies who have antibody levels measured between 14-42
 311 days after recipient of the second dose are included.
 312

Group	Inactivated vaccine (CoronaVac) (n=378)		mRNA vaccine (BNT162b2) (n=1053)		p-value*
	sVNT	(95% CI)	sVNT	(95% CI)	
Overall	53.7	(51.2, 56.3)	94.3	(93.8, 94.7)	<0.001
Age group, years					
18-29	69.6	(58.8, 80.4)	96.5	(96.2, 96.8)	<0.001
30-39	54.0	(44.1, 63.9)	94.7	(93.7, 95.6)	<0.001
40-49	53.1	(46.1, 60.2)	94.4	(93.6, 95.3)	<0.001
50-59	56.9	(52.5, 61.3)	94.0	(93.2, 94.9)	<0.001
60-69	51.6	(46.8, 56.4)	93.4	(92.1, 94.6)	<0.001
≥70	46.3	(38.9, 53.6)	92.3	(89.6, 94.9)	<0.001
Male	48.0	(43.9, 52.0)	93.3	(92.5, 94.2)	<0.001
Female	58.6	(55.4, 61.8)	95.0	(94.5, 95.4)	<0.001

313 *p-values comparing antibody levels between the two vaccines overall and in each subset of
 314 participants (i.e. each row of this table) were estimated by t-tests.
 315
 316

317 **Appendix Table 3. Mean sVNT levels measured against ancestral SARS-CoV-2 virus at**
 318 **120-180 days after the receipt of the second vaccine dose of an inactivated (CoronaVac)**
 319 **or mRNA (BNT162b2) vaccine, overall and by age and sex (n=134).** Only participants
 320 from both the EPI-HK and COVAR studies who have antibody levels measured between
 321 120-180 days after recipient of the second dose are included.
 322

Group	Inactivated vaccine (CoronaVac) (n=51)		mRNA vaccine (BNT162b2) (n=83)		p-value*
	sVNT	(95% CI)	sVNT	(95% CI)	
Overall	21.2	(16.9, 25.6)	81.1	(78.0, 84.3)	<0.001
Age group, years [†]					
18-39	- ^{††}	-	85.8	(80.8, 90.7)	<0.001
40-59	23.9	(16.1, 31.6)	79.3	(74.3, 84.2)	<0.001
≥60	18.7	(14.7, 22.8)	78.9	(72.1, 85.7)	<0.001
Male	16.5	(13.4, 19.7)	80.7	(75.9, 85.6)	<0.001
Female	24.8	(17.6, 32.0)	81.5	(77.3, 85.7)	<0.001

323 *p-values comparing antibody levels overall and in each subset between the two vaccines
 324 (i.e. each row of this table) were estimated by t-tests.

325 [†]Due to smaller sample sizes we used broader age groups in this analysis compared to the
 326 analysis shown in Appendix Table 2.

327 ^{††}Not estimated